Teva outlook cut

 

• Revenues of $3.6 billion

• GAAP diluted EPS of $0.05

• Non-GAAP diluted EPS of $0.59

• Cash flow generated from operating activities of $543 million

• Free cash flow of $685 million

• 2022 revenues outlook revised mainly due to continued foreign exchange headwinds; non-GAAP tax rate outlook range revised to 12% - 14%; operating income, Adjusted EBITDA, EPS and free cash flow reaffirmed:

• Revenues of $14.8 - $15.4 billion vs. previous range of $15.0 - $15.6 billion

• Adjusted EBITDA of $4.7 - $5.0 billion

• Non-GAAP diluted EPS of $2.40 - $2.60

• Free cash flow of $1.9 - $2.2 billion

• Non-GAAP tax rate of 12% - 14% vs. previous range of 13%-14%

• https://finance.yahoo.com/news/teva-reports-third-quarter-2022-110000361.html